Immatics (NASDAQ:IMTX) Raised to Hold at Wall Street Zen

Immatics (NASDAQ:IMTX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities research analysts also recently issued reports on IMTX. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of Immatics in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Leerink Partners reiterated an “outperform” rating and set a $17.00 price objective on shares of Immatics in a research note on Thursday, December 4th. Finally, Mizuho set a $25.00 target price on shares of Immatics in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immatics currently has an average rating of “Moderate Buy” and an average price target of $19.20.

Immatics Trading Down 2.3%

IMTX opened at $10.06 on Friday. The company’s 50 day moving average is $9.89 and its 200 day moving average is $8.93. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -9.86 and a beta of 1.36. Immatics has a 12-month low of $3.30 and a 12-month high of $12.41.

Institutional Investors Weigh In On Immatics

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC increased its position in Immatics by 3.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock worth $518,000 after purchasing an additional 1,739 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the last quarter. Barclays PLC raised its position in shares of Immatics by 11.4% during the 4th quarter. Barclays PLC now owns 28,185 shares of the company’s stock valued at $296,000 after buying an additional 2,874 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after acquiring an additional 7,116 shares during the last quarter. Finally, Virtus Investment Advisers LLC grew its position in Immatics by 43.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after acquiring an additional 7,965 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.